second-generation CYP17 lyase inhibitors (Innocrin Pharmaceuticals)

N/A

Report date: 2025/01/26 16:57:58
NME

Base Information

Drug Namesecond-generation CYP17 lyase inhibitors (Innocrin Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSteroid 17-alpha-hydroxylase inhibitorsLyases inhibitors
TargetsSteroid 17-alpha-hydroxylaseLyases
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInnocrin Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesInnocrin Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A